Myeloid neoplasms post PARP inhibitors for ovarian cancer
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2022-004190
Abstract: The incidence of myeloid neoplasms following treatment with poly (ADP-ribose) polymerase inhibitors (PARPi) in patients with ovarian cancer has been gradually increasing over the last few years. The cumulative exposure to PARPi and the improved… read more here.
Keywords: parpi; ovarian cancer; myeloid neoplasms; neoplasms post ... See more keywords